Christopher G. Bunick, MD, PhD

Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.

Bunick spoke at the Fall Clinical Dermatology Conference for PAs and NPs to discuss important considerations of biologics use for atopic dermatitis management.

Aerosolized dry shampoo is the latest personal care product to contain detectable levels of benzene, according to Bunick’s SCALE 2023 session.

Christopher Bunick, MD, PhD, comments on the role isotretinoin plays in his practice and comments on further advancements in the management of this condition.

An expert in dermatology shares his opinion on oral versus topical acne treatment options and how to assess response to treatment.

Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.

Christopher Bunick, MD, PhD, provides an overview of acne vulgaris and the populations it impacts; highlighting that this is more than just an adolescent affliction and the role of sebum production.

Christopher Bunick, MD, PhD, shares pearls from his research in benzene contamination in sunscreens and what advice he shares with patients.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.

A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.